173
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Cholestasis In Infants With Down Syndrome Is Not Due To Extrahepatic Biliary Atresia: A Ten-Year Single Egyptian Centre Experience

ORCID Icon, , ORCID Icon, , ORCID Icon, , & show all
Pages 401-408 | Published online: 22 Oct 2019

References

  • Stoll C, Dott B, Alembik Y, Roth MP. Associated congenital anomalies among cases with Down syndrome. Eur J Med Genet. 2015;58:674–680. doi:10.1016/j.ejmg.2015.11.00326578241
  • Presson AP, Partyka G, Jensen KM, et al. Current estimate of Down Syndrome population prevalence in the United States. J Pediatr. 2013;163(4):1163–1168. doi:10.1016/j.jpeds.2013.06.01323885965
  • Afifi HH, Aglan MS, Zaki ME, Thomas MM, Tosson AM. Growth charts of Down syndrome in Egypt: a study of 434 children 0–36 months of age. Am J Med Genet A. 2012;158A(11):2647–2655. doi:10.1002/ajmg.a.3546822811286
  • Arnell H, Fischler B. Population-based study of incidence and clinical outcome of neonatal cholestasis in patients with Down syndrome. J Pediatr. 2012;161:899–902. doi:10.1016/j.jpeds.2012.04.03722658787
  • Suchy FJ, Balistreri WF, Heubi JE, Searcy JE, Levin RS. Physiologic cholestasis: elevation of the primary serum bile acid concentrations in normal infants. Gastroenterology. 1981;80:1037–1041. doi:10.1016/0016-5085(81)90078-07202962
  • Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58:155–168. doi:10.1016/j.jhep.2012.08.00222885388
  • WHO International Standards for Clinical Trial Registries. ISBN 978 92 4 150429 4 (NLM classification: QV 771.4); 2012 Available from: https://apps.who.int/iris/bitstream/handle/10665/76705/9789241504294_eng.pdf;jsessionid=2DA15341BDC67DFDEDE8FC1E1F8B93D5?sequence=1 Accessed 912, 2019. doi:10.1094/PDIS-11-11-0999-PDN
  • WMA DECLARATION OF HELSINKI. WMA declaration of Helsinki - ethical principles for medical research involving human subjects, 64th. WMA general assembly; 2013 Available from https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ Accessed 912, 2019.
  • Elmagrpy Z, Rayani A, Shah A, Habas E, Aburawi EH. Down syndrome and congenital heart disease: why the regional difference as observed in the Libyan experience? Cardiovasc J Afr. 2011;22:306–309. doi:10.5830/CVJA-2010-07222159317
  • Kim MA, Lee YS, Yee NH, Choi JS, Choi JY, Seo K. Prevalence of congenital heart defects associated with down syndrome in Korea. J Korean Med Sci. 2014;29:1544–1549. doi:10.3346/jkms.2014.29.11.154425408587
  • Morsy MM, Algrigri OO, Salem SS, Abosedera MM, Abutaleb AR, Al-Harbi KM. The spectrum of congenital heart diseases in down syndrome: a retrospective study from Northwest Saudi Arabia. Saudi Med J. 2016;37:767–772. doi:10.15537/smj.2016.7.1453627381537
  • Khoury MJ, Erickson JD. Improved ascertainment of cardiovascular malformations in infants with Down’s syndrome, Atlanta, 1968 through 1989. Implications for the interpretation of increasing rates of cardiovascular malformations in surveillance systems. Am J Epidemiol. 1992;136:1457–1464. doi:10.1093/oxfordjournals.aje.a1164661288275
  • Afifi HH, Abdel Azeem AA, El-Bassyouni HT, Gheith ME, Rizk A, Bateman JB. Distinct ocular expression in infants and children with down syndrome in Cairo. EgyptMyopia Heart Dis JAMA Ophthalmol. 2013;131:1057–1066. doi:10.1001/jamaophthalmol.2013.644
  • Mokhtar MM, Abdel-Fattah M. Major birth defects among infants with Down’s syndrome in Alexandria, Egypt (1995–2000). J Trop Pediatr. 2002;48:247–249. doi:10.1093/tropej/48.4.24712200989
  • Kotb MA, Kotb A. Extrahepatic biliary atresia is an aflatoxin induced cholangiopathy in infants with null GSTM1 genotype with disrupted P53 and GSTPi to mothers heterozygous for GSTM1 polymorphism: damage control is mediated through neutrophil elastase and CD14+ activated monocytes: kotb disease. Med J Cairo Univ. 2015;83:137–145.
  • Rascón Trincado MV, Lorente Toledano F, Villalobos VS. A study of the functions of polymorphonuclear neutrophil in patients with Down’s syndrome. Allergol Immunopathol (Madr). 1988;16:339–345.2976258
  • Novo E, García MI, Lavergne J. Nonspecific immunity in Down syndrome: a study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet. 1993;46:384–391. doi:10.1002/ajmg.13204604087689298
  • Kotb MA. Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: review of a historical cohort. Dig Dis Sci. 2009;54:2231–2241. doi:10.1007/s10620-008-0600-819082720
  • Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164:9–16. doi:10.1111/j.1365-2249.2011.04335.x21352207
  • Alaama JY, Ahmad MS, Ahmad S, Damanhouri ZA. Altered Metabolism in down Syndrome, Health Problems in down Syndrome. Subrata Dey, IntechOpen; 2015 Available from https://www.intechopen.com/books/health-problems-in-down-syndrome/altered-metabolism-in-down-syndrome. doi:10.5772/60638